For example, we uncovered common variant associations of weak effect at HMGCR and NPC1L1, which encode the targets of HMG-CoA reductase inhibitors (statins) and ezetimibe, respectively, two of the most effective and commonly prescribed medications for the prevention and management of CAD through lowering blood lipid levels. This evidence concerns the gene NPC1L1 and coronary artery disorder.